NCT03494270View on ClinicalTrials.gov

High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 18, 2018

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions
ASCVD
Interventions
DRUG

Rosuvamibe

Rosuvastatin 10mg/Ezetimibe 10mg

DRUG

Monorova

Rosuvastatin 20mg

Trial Locations (1)

Unknown

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03494270 - High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients | Biotech Hunter | Biotech Hunter